38 results on '"Roussel, Jean-Christian"'
Search Results
2. Prospective clinical and biological comparison of three blood cardioplegia techniques in low-risk CABG patients: better is worse than good enough
- Author
-
Baron, Olivier, Roussel, Jean-Christian, Delaroche, Odile, Péron, Stéphanie, and Duveau, Daniel
- Subjects
- *
CORONARY artery bypass , *PEDICLE flaps (Surgery) , *INDUCED cardiac arrest , *CLINICAL trials - Abstract
Objective: Three myocardial protection techniques were evaluated in a prospective, randomised trial during coronary artery bypass grafts in 69 patients.Material and method: Twenty seven patients received intermittent hyperkalaemic undiluted warm blood anterograde cardioplegia (AC), 21 received continuous hyperkalaemic undiluted warm blood retrograde cardioplegia (RC) and 21 received intermittent, hyperkalaemic, diluted cold blood (15 °C), anterograde cardioplegia (CC). Assessment criteria were clinical, laboratory and haemodynamic.Results: Groups were homogeneous in terms of age, sex, cardiovascular risk factors, severity of coronary disease, preoperative ejection fraction, and number of bypass grafts performed. The oxygen extraction coefficient, and lactate and troponin production in the coronary sinus on aortic unclamping was not significantly different between the three groups. The base excess was
−0.19±0.13 in the RC group,−0.18±0.52 in the AC group and−2.67±0.59 in the CC group (P<0.01 CC vs. AC and CC vs. RC). The priming volume was1485±64 ml (CC),1317±44 ml (RC) and1318±30 ml (AC) (P<0.05 CC vs. AC and CC vs. RC). The haematocrit during CPB was28.9±0.9 (CC),32.5±0.8 (RC) and32±0.7 (AC) (P<0.05 CC vs. AC and CC vs. RC). The volume of crystalloid delivered was735±85 ml (CC),362±67 ml (RC) and357±105 ml (AC) (P<0.05 CC vs. AC and CC vs. RC). The incidence of ventricular fibrillation on aortic unclamping was 61.9% (CC), 9.5% (RC) and 0% (AC) (P<0.01 CC vs. AC and CC vs. RC). The transfusion rate, duration of intubation, postoperative troponin level, complication rate and mortality were not significantly different between the three groups. Haemodynamic parameters at H2, H4, H8 did not vary significantly between the three groups.Conclusion: These three techniques appear to be comparable in terms of myocardial protection. Anterograde cardioplegia ensures an identical degree of security to retrograde cardioplegia regardless of the coronary lesions, apart from redo lesions. CC requires greater haemodilution of the patients during CPB. [Copyright &y& Elsevier]- Published
- 2003
- Full Text
- View/download PDF
3. The effect of immunoglobulin immunoadsorptions on delayed xenograft rejection of human CD55 transgenic pig kidneys in baboons.
- Author
-
Ashton-Chess, Joanna, Roussel, Jean-Christian, Bernard, Pierre, Barreau, Nathalie, Karam, Georges, Dantal, Jacques, Moreau, Anne, Letessier, Eric, Nagasaka, Takaharu, Cozzi, Emanuele, Minault, David, Soulillou, Jean-Paul, and Blancho, Gilles
- Subjects
- *
IMMUNOADSORPTION , *IMMUNOGLOBULINS , *XENOGRAFTS , *KIDNEY transplantation - Abstract
Ashton-Chess J, Roussel J-C, Bernard P, Barreau N, Karam G, Dantal J, Moreau A, Letessier E, Nagasaka T, Cozzi E, Minault D, Soulillou J-P, Blancho G. The effect of immunoglobulin immunoadsorptions on delayed xenograft rejection of human CD55 transgenic pig kidneys in baboons. Xenotransplantation 2003; 10: 552–561. © Blackwell Munksgaard, 2003 Delayed xenograft rejection (DXR) remains a major obstacle in discordant xenotransplantation. As strategies of complement inhibition and xenogeneic natural antibody (Ab) removal have been shown to give prolonged xenograft survival, we endeavored to determine whether combining these two strategies would lead to an additive effect in terms of graft survival. The study was initiated with two groups, A and B, where group A received normal kidneys and group B received hCD55 transgenic kidneys. Both groups underwent pre-transplant (day − 1) total immunoglobulin (Ig) immunoadsorption (IA) and received an immunosuppression of cyclophosphamide, cyclosporine A, mycophenolate mofetil and corticosteroids. Two subsequent groups (C and D) receiving hCD55 transgenic pig kidneys were then performed with an ‘optimized’ immunosuppression (Cyclophosphamide starting 1 day earlier) but only group D recipients were immunoadsorbed. Biopsies taken during the post-transplantation period were analyzed for Ab deposition, complement activation and cellular infiltration. No hyperacute rejection was observed. In the initial immunoadsorbed groups A and B, all baboons underwent DXR, which started surprisingly early (day 5 in most cases). In the subsequent two groups, the immunoadsorbed group D baboons also underwent DXR, again as early as day 5. In contrast, group C baboons did not show any signs of DXR on their day 6 biopsy or at their time of death. Analysis of graft biopsies from the kidneys undergoing rejection or with stable function showed strong deposition of anti-Gal IgM in all cases whereas strong complement C5b-9 deposits were only observed in biopsies at rejection. Cellular infiltration consisted mostly of monocytes/macrophages, was more pronounced in biopsies taken at rejection and was associated with a pro-inflammatory environment involving interleukins 1α , 6 and 8. Our findings suggest that non-specific Ig (anti-Gal and non-Gal Ig of all isotypes) IA or even incomplete IA in immunosuppressed baboon recipients of transgenic pig kidneys is detrimental to graft survival by being associated with an Ab and complement driven rejection. We speculate that the IA were insufficient in terms of Ig depletion or frequency inducing an Ab rebound or that this total Ig depletion also removed components facilitating graft survival. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
4. Cellular participation in delayed xenograft rejection of hCD55 transgenic pig hearts by baboons.
- Author
-
Ashton-Chess, Joanna, Roussel, Jean-Christian, Manez, Rafael, Ruiz, Carmen, Moreau, Anne, Cozzi, Emanuele, Minault, David, Soulillou, Jean-Paul, and Blancho, Gilles
- Subjects
- *
XENOGRAFTS , *LABORATORY swine , *IMMUNOGLOBULINS , *TRANSGENIC animals - Abstract
Abstract: Delayed xenograft rejection (DXR) of pig organs by baboons currently represents the major obstacle to successful xenotransplantation. Although antibodies (Abs) are believed to play a fundamental role in this form of rejection, so far little is known concerning the potential cellular component. Biopsies taken during DXR of human CD55 transgenic pig hearts by non-treated (n = 2), α-Gal immunoadsorbed (n = 2), or immunosuppressed (n = 9) baboons were studied. The cellular element was explored by determining not only its phenotype by classical immunohistochemical techniques but also its activity in terms of cytokines, cytolytic enzymes and other mediators using quantitative reverse transcription polymerase chain reaction. All porcine xenografts underwent DXR; within 5 days in non-treated and immunoadsorbed animals but significantly delayed (6 to 29 days) in immunosuppressed animals. Cellular infiltration in non-immunosuppressed grafts consisted predominantly of monocytes/macrophages, CD8 cells and a few CD4 T-cells. The predominant baboon transcripts detectable were the proinflammatory cytokines interleukin1-α and tumor necrosis factor-α, the lymphokine interferon-γ and the cytotoxic enzyme granzyme B. However, these cellular components were lacking in the immunosuppressed animals. Despite these differences, strong immunoglobulin M (IgM) and C5b-9 complement deposition was observed in all animals at rejection. Together our findings suggest that although the humoral response plays a predominant role in DXR through IgM Abs and complement activation, there is a clear cellular infiltrate in DXR in this model that is likely to contribute to rejection through a strong pro-inflammatory and cytotoxic environment, necessitating substantial immunosuppression for a prolonged graft survival. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
5. Pig endothelial protein C receptor is functionally compatible with the human protein C pathway.
- Author
-
Salvaris, Evelyn J., Moran, Christopher J., Roussel, Jean Christian, Fisicaro, Nella, Robson, Simon C., and Cowan, Peter J.
- Subjects
- *
PROTEIN C , *PROTEIN receptors , *AMINO acid sequence , *SWINE , *THROMBIN , *CARRIER proteins , *THROMBIN receptors - Abstract
Background: Endothelial protein C receptor (EPCR) plays an anticoagulant and anti‐inflammatory role by promoting the activation of protein C by thrombin bound to thrombomodulin (TBM). Incompatibility between pig TBM and human/primate thrombin is thought to contribute to dysregulated coagulation in pig‐to‐primate organ xenografts, and expression of human TBM (hTBM) in pigs has shown benefit in preclinical models. However, it is not known whether there are incompatibilities—or molecular barriers—between endogenous pig EPCR (pEPCR) and transgenically expressed human TBM. Aim: To clone and express pEPCR, and determine its function in the human protein C pathway in vitro. Methods: Pig endothelial protein C receptor cDNA was generated from pig lung RNA by RT‐PCR. Primate COS‐7 transfectants expressing various combinations of human and pig TBM and EPCR were incubated with human thrombin and human protein C, and tested for TBM cofactor activity. Results: The predicted protein sequence of pEPCR shared 72.3% amino acid sequence identity with hEPCR, and residues critical for protein C binding were conserved. COS‐7 cells transfected with hEPCR, pEPCR or vector showed minimal TBM cofactor activity (0.13 ± 0.04, 0.13 ± 0.02 and 0.14 ± 0.06 U, respectively). The cofactor activity of hTBM‐transfected cells (1.18 ± 0.29 U) was 8‐fold higher than vector‐transfected cells (P =.004) and further increased 4‐fold and 3‐fold by co‐transfection with hEPCR (5.01 ± 1.12 U, P =.004) or pEPCR (3.73 ± 0.65 U, P =.003), respectively. Conclusions: Our data show that pEPCR is largely compatible with the human TBM/thrombin complex, when expressed on COS‐7 cells in vitro, promoting the activation of human protein C. These findings suggest that endogenous pEPCR will enhance the activity of transgenic hTBM in the xenograft setting. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Long-Term Outcome and Prognosis of Noninfectious Thoracic Aortitis.
- Author
-
Espitia, Olivier, Bruneval, Patrick, Assaraf, Morgane, Pouchot, Jacques, Liozon, Eric, de Boysson, Hubert, Gaudric, Julien, Chiche, Laurent, Achouh, Paul, Roussel, Jean-Christian, Miranda, Sébastien, Mirault, Tristan, Boussouar, Samia, Redheuil, Alban, Serfaty, Jean-Michel, Bénichou, Antoine, Agard, Christian, Guédon, Alexis F., Cacoub, Patrice, and Paraf, François
- Subjects
- *
AORTITIS , *PROGNOSIS , *GIANT cell arteritis , *TAKAYASU arteritis - Published
- 2023
- Full Text
- View/download PDF
7. Inverse probability weighting to control confounding in an illness-death model for interval-censored data.
- Author
-
Gillaizeau, Florence, Sénage, Thomas, Le Borgne, Florent, Le Tourneau, Thierry, Roussel, Jean‐Christian, Leffondrè, Karen, Porcher, Raphaël, Giraudeau, Bruno, Dantan, Etienne, Foucher, Yohann, and Roussel, Jean-Christian
- Abstract
Multistate models with interval-censored data, such as the illness-death model, are still not used to any considerable extent in medical research regardless of the significant literature demonstrating their advantages compared to usual survival models. Possible explanations are their uncommon availability in classical statistical software or, when they are available, by the limitations related to multivariable modelling to take confounding into consideration. In this paper, we propose a strategy based on propensity scores that allows population causal effects to be estimated: the inverse probability weighting in the illness semi-Markov model with interval-censored data. Using simulated data, we validated the performances of the proposed approach. We also illustrated the usefulness of the method by an application aiming to evaluate the relationship between the inadequate size of an aortic bioprosthesis and its degeneration or/and patient death. We have updated the R package multistate to facilitate the future use of this method. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Differential Immune Response to Bioprosthetic Heart Valve Tissues in the α1,3Galactosyltransferase-Knockout Mouse Model.
- Author
-
Casós, Kelly, Llatjós, Roger, Blasco-Lucas, Arnau, Kuguel, Sebastián G., Sbraga, Fabrizio, Galli, Cesare, Padler-Karavani, Vered, Le Tourneau, Thierry, Vadori, Marta, Perota, Andrea, Roussel, Jean-Christian, Bottio, Tomaso, Cozzi, Emanuele, Soulillou, Jean-Paul, Galiñanes, Manuel, Máñez, Rafael, and Costa, Cristina
- Subjects
- *
BIOPROSTHETIC heart valves , *IMMUNOGLOBULINS , *IMMUNE response , *LABORATORY mice , *ANIMAL disease models , *TISSUES - Abstract
Structural valve deterioration (SVD) of bioprosthetic heart valves (BHVs) has great clinical and economic consequences. Notably, immunity against BHVs plays a major role in SVD, especially when implanted in young and middle-aged patients. However, the complex pathogenesis of SVD remains to be fully characterized, and analyses of commercial BHVs in standardized-preclinical settings are needed for further advancement. Here, we studied the immune response to commercial BHV tissue of bovine, porcine, and equine origin after subcutaneous implantation into adult α1,3-galactosyltransferase-knockout (Gal KO) mice. The levels of serum anti-galactose α1,3-galactose (Gal) and -non-Gal IgM and IgG antibodies were determined up to 2 months post-implantation. Based on histological analyses, all BHV tissues studied triggered distinct infiltrating cellular immune responses that related to tissue degeneration. Increased anti-Gal antibody levels were found in serum after ATS 3f and Freedom/Solo implantation but not for Crown or Hancock II grafts. Overall, there were no correlations between cellular-immunity scores and post-implantation antibodies, suggesting these are independent factors differentially affecting the outcome of distinct commercial BHVs. These findings provide further insights into the understanding of SVD immunopathogenesis and highlight the need to evaluate immune responses as a confounding factor. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. The MIDA-Q Mortality Risk Score: A Quantitative Prognostic Tool for the Mitral Valve Prolapse Spectrum.
- Author
-
Essayagh, Benjamin, Benfari, Giovanni, Antoine, Clemence, Grigioni, Francesco, Le Tourneau, Thierry, Roussel, Jean-Christian, Bax, Jeroen J., Delgado, Victoria, Ajmone Marsan, Nina, van Wijngaarden, Aniek, Tribouilloy, Christophe, Rusinaru, Dan, Hochstadt, Aviram, Topilsky, Yan, Thapa, Prabin, Michelena, Hector I., and Enriquez-Sarano, Maurice
- Subjects
- *
MITRAL valve prolapse , *DISEASE risk factors , *PROGNOSTIC tests , *MITRAL valve insufficiency - Abstract
Background: Mitral valve prolapse (MVP) is responsible for a considerable disease burden but is widely heterogeneous. The lack of a comprehensive prognostic instrument covering the entire MVP spectrum, encompassing the quantified consequent degenerative mitral regurgitation (DMR), hinders clinical management and therapeutic trials. Methods: The new Mitral Regurgitation International Database Quantitative (MIDA-Q) registry enrolled 8187 consecutive patients (ages 63±16 years, 47% women, follow-up 5.5±3.3 years) first diagnosed with isolated MVP, without or with DMR quantified prospectively (measuring effective regurgitant orifice [ERO] and regurgitant volume) in routine practice of 5 tertiary care centers from North America, Europe, and the Middle East. The MIDA-Q score ranges from 0 to 15 by accumulating guideline-based risk factors and DMR severity. Long-term survival under medical management was the primary outcome end point. Results: MVP was associated with DMR absent/mild (ERO <20 mm2) in 50%, moderate (ERO 20–40 mm2) in 25%, and severe or higher (ERO ≥40 mm2) in 25%, with mean ERO 24±24 mm2, regurgitant volume 37±35 mL. Median MIDA-Q score was 4 with a wide distribution (10%–90% range, 0–9). MIDA-Q score was higher in patients with EuroScore II ≥1% versus <1% (median, 7 versus 3; P < 0.0001) but with wide overlap (10%–90% range, 4–11 versus 0–7) and mediocre correlation (R 2 0.18). Five-year survival under medical management was strongly associated with MIDA-Q score, 97±1% with score 0, 95±1% with score 1 to 2, 82±1% with score 3 to 4, 67±1% with score 5 to 6, 60±1% with score 7 to 8, 44±1% with score 9 to 10, 35±1% with score 11 to 12, and 5±4% with MIDA-Q score ≥13, with hazard ratio 1.31 [1.29–1.33] per 1-point increment. Excess mortality with higher MIDA-Q scores persisted after adjustment for age, sex, and EuroScore II (adjusted hazard ratio, 1.13 [1.11–1.15] per 1-point increment). Subgroup analysis showed persistent association of MIDA-Q score with mortality in all possible subsets, in particular, with EuroScore II<1% (hazard ratio, 1.08 [1.02–1.14]) or ≥1% (hazard ratio, 1.11 [1.08–1.13]) and with no/mild DMR (hazard ratio, 1.14 [1.10–1.19]) or moderate/severe DMR (hazard ratio, 1.13 [1.10–1.16], all per 1-point increment with P <0.0001). Nested-model and bootstrapping analyses demonstrated incremental prognostic power of MIDA-Q score (all P <0.0001). Conclusions: This large, international cohort of isolated MVP, with prospective DMR quantification in routine practice, demonstrates the wide range of risk factor accumulation and considerable heterogeneity of outcomes after MVP diagnosis. The MIDA-Q score is strongly, independently, and incrementally associated with long-term survival after MVP diagnosis, irrespective of presentation, and is therefore a crucial prognostic instrument for risk stratification, clinical trials, and management of patients diagnosed with all forms of MVP. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Management and outcomes of ventricular septal defects after acute myocardial infarction: A multicenter retrospective study.
- Author
-
Piriou, Pierre‐Guillaume, Guerin, Patrice, Plessis, Julien, Senage, Thomas, Manigold, Thibaut, Auffret, Vincent, Didier, Romain, Le Ruz, Robin, David, Charles‐Henri, Roussel, Jean‐Christian, and Letocart, Vincent
- Subjects
- *
VENTRICULAR septal defects , *INTRA-aortic balloon counterpulsation , *MYOCARDIAL infarction , *EXTRACORPOREAL membrane oxygenation , *VENTRICULAR septal rupture ,MORTALITY risk factors - Abstract
Background and Aim: The mortality rate of patients with post‐myocardial infarction (MI) ventricular septal defects (VSDs) is high, and the benefit of surgery is unclear. We aimed to investigate the management and outcomes of post‐MI VSD over a 10‐year period in a large cohort. Methods: Data of patients with post‐MI VSD admitted in three French university hospitals from 2008 to 2019 were examined. The characteristics of those who underwent surgery were compared with those who received medical treatment. Mortality risk factors, survival curves, and outcomes at 30 days and 1 year after treatment were determined. Results: Of the 92 patients whose data were examined, 50 underwent surgery and 42 received exclusive medical treatment. All patients were critically ill. Overall, 76.1% of patients received inotropic support, and 63% received mechanical ventilation. Circulatory assistance, mainly via intra‐aortic balloon pump and extra‐corporeal membrane oxygenation, was provided to 46.7% patients, with 14.1% requiring a second assistance. The median time to surgery was 4 days. At 1 year, mortality was 46% in those who underwent surgery and 83.3% in those treated medically (p <.001). Survival curves at 1 and 3 months showed major differences, and the survival rate showed little change 30 days after treatment. Cardiogenic shock and cardiac arrest emerged as risk factors for mortality. Conclusions: In our retrospective, multicenter study, the mortality resulting from post‐MI VSD did not seem to improve over the last decade. Although surgery carried considerable risks, it improved survival. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation.
- Author
-
Smadja, David M., Ivak, Peter, Pya, Yuri, Latremouille, Christian, Gustafsson, Finn, Roussel, Jean Christian, Vincentelli, Andre, Flecher, Erwan, Jansen, Piet, and Netuka, Ivan
- Subjects
- *
LOW-molecular-weight heparin , *ARTIFICIAL hearts , *ANTICOAGULANTS - Published
- 2022
- Full Text
- View/download PDF
12. Heritability of aortic valve stenosis and bicuspid enrichment in families with aortic valve stenosis.
- Author
-
Boureau, Anne-Sophie, Karakachoff, Matilde, Le Scouarnec, Solena, Capoulade, Romain, Cueff, Caroline, de Decker, Laure, Senage, Thomas, Verhoye, Jean-Philippe, Baufreton, Christophe, Roussel, Jean-Christian, Dina, Christian, Probst, Vincent, Schott, Jean-Jacques, and Le Tourneau, Thierry
- Subjects
- *
AORTIC stenosis , *MITRAL valve , *HERITABILITY , *AORTIC valve , *AORTIC valve transplantation , *TRICUSPID valve insufficiency - Abstract
Although a familial component of calcific aortic valve stenosis (CAVS) has been described, its heritability remains unknown. Hence, we aim to assess the heritability of CAVS and the prevalence of bicuspid aortic valve among CAVS families. Probands were recruited following aortic valve replacement (AVR) for severe CAVS on either tricuspid (TAV) or bicuspid aortic valve (BAV). After screening, relatives underwent a Doppler-echocardiography to assess the aortic valve morphology as well as the presence and severity of CAVS. Families were classified in two types according to proband's aortic valve phenotype: TAV or BAV families. Control families were recruited and screened for the presence of BAV. Among the 2371 relatives from 138 CAVS families (pedigree cohort), heritability of CAVS was significant (h2 = 0.47, p < 0.0001), in TAV (h2 = 0.49, p < 0.0001) and BAV families (h2 = 0.50, p < 0.0001). The prevalence of BAV in 790 relatives (phenotype cohort) was significantly increased in both TAV and BAV families compared to control families with a prevalence ratio of 2.6 ([95%CI:1.4–5.9]; p = 0.005) and 4.6 ([95%CI:2.4–13.4]; p < 0.0001), respectively. At least one relative had a BAV in 22.2% of tricuspid CAVS families. Our study confirms the heritability of CAVS in both TAV and BAV families, suggesting a genetic background of this frequent valvular disease. In addition, BAV enrichment in TAV families suggests an interplay between tricuspid CAVS and BAV. Overall results support the need to improve phenotyping (i.e. BAV, TAV, risk factors) in CAVS families in order to enhance the identification of rare and causal genetic variants of CAVS. Clinical Trials Identifier: NCT02890407. • Heritability of CAVS was significant, reinforcing the hypothesis of a genetic background • The enrichment of BAV phenotype in relatives of tricuspid CAVS was significant. • The results support the need to improve phenotyping in CAVS families to enhance the identification of genetic variants of CAVS. • The clinicians should be aware of the heritability of CAVS for questioning patients about familial history of CAVS. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Survival after biventricular mechanical circulatory support: Does the type of device matter?
- Author
-
Kirsch, Matthias, Mazzucotelli, Jean-Philippe, Roussel, Jean-Christian, Bouchot, Olivier, N'Loga, Joseph, Leprince, Pascal, Litzler, Pierre-Yves, and Vincentelli, André
- Subjects
- *
HEART assist devices , *HEART transplant recipients , *COMPLICATIONS of artificial hearts , *STATISTICS , *STROKE ,HEART transplantation complications - Abstract
Background: Biventricular support can be achieved using paracorporeal biventricular assist devices (BiVADs), the total artificial heart (TAH), and implantable VADs. This study evaluated the influence of the device on patient survival. Methods: Data from 383 patients (321 men [84%]) undergoing primary, planned biventricular support using durable devices between 2000 and 2010 were extracted from the French multicentric Groupe de Réflexion sur l''Assistance Mécanique (GRAM) registry. Mean age was 41.6 ± 14.0 years. Patients were classified as group 1, 255 (67%) with paracorporeal BiVADs; group 2, 90 (24%) with TAH; and group 3, 38 (10%) with implantable BiVADs. Results: Mean patient support duration was 82.8 ± 107.4 days and similar among groups (p = 0.53). Bridging to transplantation was successful in 211 patients (55%) and to recovery in 23 (6%). Mortality on device was similar among groups (p = 0.16). TAH patients had a significantly lower stroke rate (p < 0.0001). Actuarial estimates for survival while on support were 75.2% ± 2.3%, 64.4% ± 2.7%, 61.1% ± 2.8%, and 56.8% ± 3.1% at 30, 60, 90, and 180 days, respectively, and were similar among groups. However, TAH patients undergoing prolonged support (≥90 days) showed a trend toward improved survival (p = 0.08). Actuarial post-transplant survival estimates were, respectively, 81.7 ± 2.7, 75.3 ± 3.0, 73.0 ± 3.0, and 64.7 ± 3.7 at 1 month and 1, 3, and 5 years and were similar among groups (p = 0.84). Conclusion: Survival while on support and after heart transplantation did not differ significantly in patients supported with paracorporeal BiVADs, implantable BiVADs, or the TAH. Patients undergoing prolonged support (>90 days) tended to have improved survival when supported with TAH compared with BiVADs, which may be related to a lower incidence of neurologic events. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
14. Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography–computerised tomography in patients with non-small-cell lung cancer
- Author
-
Perigaud, Christian, Bridji, Boumédiène, Roussel, Jean Christian, Sagan, Christine, Mugniot, Antoine, Duveau, Daniel, Baron, Olivier, and Despins, Philippe
- Subjects
- *
LYMPH nodes , *POSITRON emission tomography , *SMALL cell lung cancer , *LONGITUDINAL method , *PREOPERATIVE care , *LUNG cancer treatment , *SENSITIVITY & specificity (Statistics) , *PATIENTS - Abstract
Abstract: Objective: Mediastinal lymph node staging determines the treatment strategy for non-small-cell lung cancer. This study aims to evaluate prospectively the accuracy of preoperative integrated 18-fluoro-2-deoxy-d-glucose positron emission tomography–computerised tomography (18FDG PET-CT) for mediastinal lymph node staging. Methods: Preoperative integrated 18FDG PET-CT was used to analyse mediastinal lymph nodes in patients with non-small-cell lung cancer. Nodal stations were identified according to the American Thoracic Society mapping system. Lymph nodes with a standardised uptake value (SUVmax) >3 were considered to be positive. The mediastinal lymph nodes were harvested during lung resection and the results of integrated 18FDG PET-CT were compared to the mediastinal lymph node histology results. Results: A total of 51 patients were enrolled in this study. The mean interval between integrated 18FDG PET-CT and surgery was 31±15.8 days (range: 2–78 days). The mean mediastinal lymph node harvested and station number per patient during surgery were 11.8±5.6 (range: 2–27) and 3.8±1 (range: 2–6), respectively. The incidence of N2 pathological disease was 19.6%. The integrated 18FDG PET-CT sensitivity and specificity were 40±30% and 85±11%, respectively. The positive and negative predictive values were 40±30% and 85±11%, respectively. False-positive results (six patients) were mainly due to inflammatory lymph nodes. False-negative results (six patients) were mainly due to infra-centimetrical, malignant lymph node invasion. Conclusion: The sensitivity of integrated 18FDG PET-CT for mediastinal lymph node staging in patients selected for surgery is low. When positive mediastinal lymph nodes are detected, invasive mediastinal staging must be performed. On the other hand, the specificity is high: patients with negative integrated 18FDG PET-CT can be operated upon without invasive mediastinal staging. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
15. Recombinant pig TFPI efficiently regulates human tissue factor pathways.
- Author
-
Lee, K. F. Eddy, Salvaris, Evelyn J., Roussel, Jean-Christian, Robson, Simon C., d'Apice, Anthony J. F., and Cowan, Peter J.
- Subjects
- *
SWINE , *PRIMATES , *XENOGRAFTS , *THROMBOSIS , *BLOOD coagulation , *AORTA , *ENDOTHELIUM , *ANTICOAGULANTS - Abstract
Rejected pig-to-primate organ xenografts almost invariably exhibit significant microvascular thrombosis, believed to be due in part to several molecular incompatibilities affecting the regulation of coagulation. In this study, we tested one such proposed incompatibility: whether there is, at least in part, a functional incompatibility in pig tissue factor pathway inhibitor (TFPI) that impedes binding of human factor Xa and regulation of human tissue factor-initiated coagulation. TFPIα cDNA was cloned from pig aortic endothelial cells and found to encode a 279-residue mature protein with 79% overall identity to human TFPIα, increasing to 88 to 90% in the functional Kunitz-1 and Kunitz-2 domains. Transfected primate cells expressing equivalent levels of GPI-linked pig or human TFPIα were assayed for binding of human factor Xa and inhibition of the human factor VIIa/tissue factor complex. The activity of the expressed pig anticoagulant was equivalent to that of the human protein in both measures of TFPI function in these systems. These data indicate that there are no apparent incompatibilities between recombinant pig TFPI and the human tissue factor pathway. Other factors must account for the thromboregulatory failure of pig endothelium and aberrant tissue factor activity in xenograft rejection. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
16. Carotid versus femoral access for transcatheter aortic valve replacement: comparable results in the current era.
- Author
-
Marie, Basile, David, Charles Henri, Guimbretière, Guillaume, Foucher, Yohann, Buschiazzo, Antoine, Letocart, Vincent, Manigold, Thibaut, Plessis, Julien, Jaafar, Philippe, Morin, Hélène, Rozec, Bertrand, Roussel, Jean Christian, and Sénage, Thomas
- Subjects
- *
HEART valve prosthesis implantation , *PERIPHERAL vascular diseases , *AORTIC valve insufficiency - Abstract
Open in new tab Download slide Open in new tab Download slide OBJECTIVES The carotid approach for transcatheter aortic valve replacement (TAVR) has been shown to be feasible and safe. The goal of this study was to compare the 30-day outcomes of trans-carotid (TC) and transfemoral (TF) TAVR. METHODS This retrospective study enrolled 500 consecutive patients treated by TC-TAVR (n = 100) or TF-TAVR (n = 400) with percutaneous closure between January 2018 and January 2020 at the Nantes University Hospital. The primary end-point was the occurrence of cardiovascular death and cerebrovascular events at 30 days. RESULTS The mean age was 79.9 ± 8.1 in the TC group and 81.3 ± 6.9 (P = 0.069) in the TF group. The TC group had more men (69% vs 50.5%; P = 0.001) and more patients with peripheral vascular disease (86% vs 14.8%; P < 0.0001). Cardiac characteristics were similar between the groups, and the EuroSCORE II was 3.8 ± 2.6% vs 4.6 ± 6.0%, respectively (P = 0.443). The 30-day mortality was 2% in the TC group versus 1% in the TF group (P = 0.345). TC-TAVR was not associated with an increased risk of stroke (2% vs 2.5%; P = 0.999) or major vascular complications (2% vs 4%; P = 0.548). More permanent pacemakers were implanted in the TF group (14.9% vs 5.6%; P = 0.015), and no moderate or severe aortic regurgitation was observed in the TC group (0 vs 3.3%; P = 0.08). TC-TAVR was not associated with an increased risk of mortality or stroke at 30 days (odds ratio 1.32; 95% confidence interval 0.42–4.21; P = 0.63) in the multivariable analysis. CONCLUSIONS No statistically significant differences between TC-TAVR and TF-TAVR were observed; therefore, TC-TAVR should be the first alternative in patients with anatomical contraindications to the femoral route. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Success of Thrombectomy in Management of Ischemic Stroke in Two Patients with SynCardia Total Artificial Heart in Bridge-to-Transplantation.
- Author
-
Le Picault, Brendan, David, Charles-Henri, Alexandre, Pierre-Louis, Lenoble, Cédric, Bizouarn, Philippe, Lepoivre, Thierry, Groleau, Nicolas, Rozec, Bertrand, Desal, Hubert, Roussel, Jean-Christian, and Sénage, Thomas
- Subjects
- *
ISCHEMIC stroke , *STROKE patients , *THROMBECTOMY , *ARTIFICIAL hearts , *HEART failure , *HEART transplantation , *HEART assist devices , *CARDIAC pacing - Abstract
Introduction: Circulatory assistance from a SynCardia Total Artificial Heart (SynCardia-TAH) is a reliable bridge-to-transplant solution for patients with end-stage biventricular heart failure. Ischemic strokes affect about 10% of patients with a SynCardia-TAH. We report for the first time in the literature two successful thrombectomies to treat the acute phase of ischemic stroke in two patients treated with a SynCardia-TAH in the bridge-to-transplant (BTT). Case report: We follow two patients with circulatory support from a SynCardia-TAH in the bridge-to-transplant for terminal biventricular cardiac failure with ischemic stroke during the support period. An early in-hospital diagnosis enables the completion of a mechanical thrombectomy within the first 6 h of the onset of symptoms. There was no intracranial hemorrhagic complication during or after the procedure and the patients fully recovered from neurological deficits, allowing a successful heart transplant. Conclusion: This case report describes the possibility of treating ischemic strokes under a SynCardia-TAH by mechanical thrombectomy following the same recommendations as for the general population with excellent results and without any hemorrhagic complication during or after the procedure. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Celsior ® crystalloid cardioplegia versus standard hyperkalemic normothermic blood cardioplegia: Analysis of myocardial protection in elective mitral valve repair.
- Author
-
Pontailler, Margaux, David, Charles-Henri, Lacoste, Philippe, Guimbretière, Guillaume, Marie, Basile, Perigaud, Christian, Mugniot, Antoine, Fellah, Imen, Roussel, Jean-Christian, and Senage, Thomas
- Subjects
- *
MITRAL valve surgery , *CARDIAC surgery , *ELECTIVE surgery , *TROPONIN , *LENGTH of stay in hospitals , *SCIENTIFIC observation , *ACADEMIC medical centers , *SOCIAL support , *MULTIPLE regression analysis , *RETROSPECTIVE studies , *T-test (Statistics) , *CHI-squared test , *DESCRIPTIVE statistics , *HYPERKALEMIA , *ELECTRIC countershock , *CARDIAC pacemakers , *PATIENT safety - Abstract
Introduction: With the increase and refinement of video assisted mitral valve surgery, cristalloïd cardioplegia started regaining popularity. The aim of our study was to evaluate the effectiveness of Celsior®, a crystalloid cardioplegic solution, on myocardial protection in elective surgical mitral valve repair in comparison to blood based hyperkalemic cardioplegia. Methods: In this observational retrospective study, all consecutive elective isolated surgical mitral valve repair where Celsior® or normothermic hyperkalemic blood cardioplegia were used were included. Primary endpoint was any sign of myocardial protection failure (troponin levels, need for inotropic or mechanical support, rhythm disturbances, mortality). Secondary endpoint was Celsior® safety (allergic reactions, bleeding, organ toxicities). Results: From January 2009 to August 2016, 382 patients underwent elective isolated mitral valve repair in whom normothermic hyperkalemic blood cardioplegia (n = 181) or Celsior® (n = 201) were used. There were no statistically significant differences in baseline characteristics including Euroscore 2. Peak troponin (pg/ml) release and 30-days mortality were not statistically different. Need for cardioversion was significantly more frequent in the Celsior® group (47% vs 13%, p < 0.001). There was no statistical difference in post-operative atrial fibrillation, permanent pacemaker implantation, reoperation for bleeding, transfusion, acute kidney injury, haemoglobin at discharge or length of stay. No allergic reaction to Celsior® occurred. Conclusion: Effective myocardial protection was achieved with the Celsior® cardioplegic solution with no unexpected toxicity. Celsior® may be an efficacious and safe cardioprotective strategy in mitral valve repair. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Response by Essayagh et al to Letter Regarding Article, "The MIDA-Q Mortality Risk Score: A Quantitative Prognostic Tool for the Mitral Valve Prolapse Spectrum".
- Author
-
Essayagh, Benjamin, Benfari, Giovanni, Antoine, Clemence, Grigioni, Francesco, Le Tourneau, Thierry, Roussel, Jean-Christian, Bax, Jeroen J., Marsan, Nina Ajmone, van Wijngaarden, Aniek, Tribouilloy, Christophe, Rusinaru, Dan, Hochstadt, Aviram, Topilsky, Yan, Thapa, Prabin, Michelena, Hector I., and Enriquez-Sarano, Maurice
- Subjects
- *
MITRAL valve prolapse , *DISEASE risk factors , *PROGNOSTIC tests , *MORTALITY - Published
- 2023
- Full Text
- View/download PDF
20. A heart transplant after total artificial heart support: initial and long-term results.
- Author
-
David, Charles-Henri, Lacoste, Philippe, Nanjaiah, Prakash, Bizouarn, Philippe, Lepoivre, Thierry, Michel, Magali, Pattier, Sabine, Toquet, Claire, Périgaud, Christian, Mugniot, Antoine, Habash, Ousama Al, Petit, Thierry, Groleau, Nicolas, Rozec, Bertrand, Trochu, Jean Noel, Roussel, Jean Christian, and Sénage, Thomas
- Subjects
- *
ARTIFICIAL hearts , *HEART transplantation , *SURVIVAL analysis (Biometry) , *INTENSIVE care units , *KIDNEY transplantation , *HOSPITAL mortality - Abstract
OBJECTIVES Open in new tab Download slide Open in new tab Download slide At our centre, the SynCardia temporary Total Artificial Heart (TAH-t) (SynCardia Systems, LLC, Tucson, AZ, USA) is used to provide long-term support for patients with biventricular failure as a bridge to a transplant. However, a heart transplant (HT) after such support remains challenging. The aim of this retrospective study was to assess the immediate and long-term results following an HT in the cohort of patients who had a TAH-t implant. METHODS A total of 73 patients were implanted with the TAH-t between 1988 and 2019 in our centre. Of these 73 consecutive patients, 50 (68%) received an HT and are included in this retrospective analysis of prospectively collected data. RESULTS In the selected cohort, in-hospital mortality after an HT was 10% (n = 5). The median intensive care unit stay was 33 days (range 5–278). The median hospital stay was 41 days (range 28–650). A partial or total pericardiectomy was performed during the HT procedure in 21 patients (42%) due to a severe pericardial reaction. Long-term survival rates after an HT at 5, 10 and 12 years were 79.1 ± 5.9% (n = 32), 76.5 ± 6.3% (n = 22) and 72.4 ± 7.1% (n = 12), respectively, which was similar to the long-term survival for a primary HT without TAH-t during the same period (n = 686). An HT performed within 3–6 months post-TAH-t implantation appeared to provide the best survival (P = 0.007). Eight (16%) patients required chronic dialysis during the subsequent follow-up period, with 3 patients requiring a kidney transplant. CONCLUSIONS The long-term outcomes with the SynCardia TAH-t as a bridge to transplant in patients with severe biventricular failure are very encouraging. Our review noted that an HT following TAH-t can be technically challenging, especially in the case of a severe pericardial reaction, with potential pitfalls that should be recognized preoperatively. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. The centrifuge brake impacts neither routine coagulation assays nor platelet count in platelet-poor plasma.
- Author
-
Boissier, Elodie, Lakhal, Karim, Talon, Laurie, Senage, Thomas, Rozec, Bertrand, Roussel, Jean-Christian, Sinegre, Thomas, and Lebreton, Aurélien
- Subjects
- *
PLATELET count , *BLOOD coagulation , *CENTRIFUGES - Published
- 2020
- Full Text
- View/download PDF
22. Durability of bioprosthetic aortic valves in patients under the age of 60 years - rationale and design of the international INDURE registry.
- Author
-
Meuris, Bart, Borger, Michael A., Bourguignon, Thierry, Siepe, Matthias, Grabenwöger, Martin, Laufer, Günther, Binder, Konrad, Polvani, Gianluca, Stefano, Pierluigi, Coscioni, Enrico, van Leeuwen, Wouter, Demers, Philippe, Dagenais, Francois, Canovas, Sergio, Theron, Alexis, Langanay, Thierry, Roussel, Jean-Christian, Wendler, Olaf, Mariscalco, Giovanni, and Pessotto, Renzo
- Subjects
- *
AORTIC valve , *AORTIC valve transplantation , *CORONARY artery bypass , *RELIEF valves , *DURABILITY , *HEART valve prosthesis implantation , *PERCUTANEOUS balloon valvuloplasty - Abstract
Background: There is an ever-growing number of patients requiring aortic valve replacement (AVR). Limited data is available on the long-term outcomes and structural integrity of bioprosthetic valves in younger patients undergoing surgical AVR.Methods: The INSPIRIS RESILIA Durability Registry (INDURE) is a prospective, open-label, multicentre, international registry with a follow-up of 5 years to assess clinical outcomes of patients younger than 60 years who undergo surgical AVR using the INSPIRIS RESILIA aortic valve. INDURE will be conducted across 20-22 sites in Europe and Canada and intends to enrol minimum of 400 patients. Patients will be included if they are scheduled to undergo AVR with or without concomitant root replacement and/or coronary bypass surgery. The primary objectives are to 1) determine VARC-2 defined time-related valve safety at one-year (depicted as freedom from events) and 2) determine freedom from stage 3 structural valve degeneration (SVD) presenting as morphological abnormalities and severe haemodynamic valve degeneration at 5 years. Secondary objectives include the assessment of the haemodynamic performance of the valve, all stages of SVD, potential valve-in-valve procedures, clinical outcomes (in terms of New York Heart Association [NYHA] function class and freedom from valve-related rehospitalisation) and change in patient quality-of-life.Discussion: INDURE is a prospective, multicentre registry in Europe and Canada, which will provide much needed data on the long-term performance of bioprosthetic valves in general and the INSPIRIS RESILIA valve in particular. The data may help to gather a deeper understanding of the longevity of bioprosthetic valves and may expand the use of bioprosthetic valves in patients under the age of 60 years.Trial Registration: ClinicalTrials.gov identifier: NCT03666741 (registration received September, 12th, 2018). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
23. Romiplostim as a transfusion saving strategy in 20 patients after heart or lung transplantation: a single centre before-after pilot study.
- Author
-
Vourc'h, Mickael, Senage, Thomas, Lepoivre, Thierry, Volteau, Christelle, Fortuit, Camille, Pattier, Sabine, Guimbretiere, Guillaume, Roussel, Jean-Christian, and Rozec, Bertrand
- Subjects
- *
ACADEMIC medical centers , *BLOOD platelet transfusion , *COLONY-stimulating factors (Physiology) , *CONFIDENCE intervals , *RED blood cell transfusion , *GRAFT rejection , *HEART transplantation , *INTENSIVE care units , *LUNG transplantation , *PATIENTS , *PLASMA exchange (Therapeutics) , *POSTOPERATIVE period , *QUALITY assurance , *SURGERY , *THROMBOCYTOPENIA , *VENOUS thrombosis , *PILOT projects , *TREATMENT effectiveness , *PRE-tests & post-tests , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *HOSPITAL mortality , *PLATELET count - Abstract
Background: Thrombocytopenia is a common disorder after heart or lung transplantation. Platelet transfusion is often required to maintain haemostasis but represents a specific cause of morbidity and mortality in this setting including alloimmunisation and graft rejection. Study design and methods: As part of a health-care quality improvement project, in a single-centre before–after pilot study, the relevance of a platelet transfusion saving strategy based on romiplostim administration after transplantation was assessed in patients with platelet count <100 × 109/L. Transfusions on days 28 and 90 were compared using propensity matched score for adjustment of demographic characteristics at baseline. The primary outcome was platelet transfusion until day 28 after transplantation. Results: Ninety-three patients were analysed (73 before vs. 20 after). The median [interquartile range] number of platelet concentrate was 1 [0;4.0] before versus 0.5 [0;2.0] in the after period, mean difference 0.5 confidence interval 95% [−0.7 to 1.7], p = 0.39. On day 28, median [interquartile range] red blood cell transfusion was significantly higher in the before versus the after period, 7 [2.0;13.5] versus 6 [1.5;8.5], mean difference 3.2 CI 95% [0.4-6.0], p = 0.02. At 6 months, the rate of patients with de novo anti-human leukocyte antigen alloimmunisation was 45% before versus 53% in the after period (p = 0.56). Deep venous thrombosis was detected in nine patients (12%) before versus seven patients (35%) in the after period (p = 0.04). Conclusion: Romiplostim did not significantly reduce platelet transfusion after heart or lung transplantation. Its relevance and safety in a global transfusion strategy remains to be studied in this setting in a large randomised study. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. A simplified delivery frozen elephant trunk technique to reduce circulatory arrest time in hybrid aortic arch surgery.
- Author
-
Sénage, Thomas, Bonnet, Nicolas, Guimbretière, Guillaume, David, Charles‐Henri, Roussel, Jean‐Christian, and Braunberger, Eric
- Abstract
A simplified delivery technique for the frozen elephant trunk procedure allows the distal suture to be performed on a perfused and loaded aorta in moderate hypothermia—or even normothermia—reducing circulatory arrest time to just a few minutes. Two surgical sealing tourniquets are placed around the aortic arch, usually between the brachiocephalic trunk (BCT) and the left common carotid artery and the aorta is cross‐clamped and cardioplegia started. Once in mild hypothermia, the BCT is disconnected and circulatory arrest is initiated while cerebral perfusion is maintained. This modified technique can be used in all pathologies, including dissections. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Haemolysis index: validation for haemolysis detection during extracorporeal membrane oxygenation.
- Author
-
Boissier, Elodie, Lakhal, Karim, Senage, Thomas, Bizouarn, Philippe, Lepoivre, Thierry, Nicolet, Johanna, Roussel, Jean-Christian, Rozec, Bertrand, Vourc'h, Mickael, and Bigot-Corbel, Edith
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *MECONIUM aspiration syndrome , *ELECTROLYTE analysis , *ACUTE kidney failure , *RECEIVER operating characteristic curves , *LIGHT absorbance , *ERYTHROCYTES - Published
- 2020
- Full Text
- View/download PDF
26. A bioprosthetic total artificial heart for end-stage heart failure: Results from a pilot study.
- Author
-
Latrémouille, Christian, Carpentier, Alain, Leprince, Pascal, Roussel, Jean-Christian, Cholley, Bernard, Boissier, Elodie, Epailly, Eric, Capel, Antoine, Jansen, Piet, and Smadja, David M.
- Subjects
- *
HEART failure , *BIOPROSTHESIS , *CARDIAC surgery , *ARTIFICIAL hearts , *ARTIFICIAL blood circulation - Abstract
Background The electro-hydraulically actuated Carmat total artificial heart (C-TAH) is designed to replace the heart in patients with end-stage heart failure, either as bridge to transplant or destination therapy. It provides pulsatile flow and contains bio-prosthetic blood contacting materials. A clinical feasibility study was conducted to evaluate the C-TAH safety and performance. Methods Hospitalized patients, at imminent risk of death from irreversible biventricular failure despite optimal medical management, and not eligible for transplant or eligible but on extracorporeal life support, were enrolled. The primary endpoint was 30-days survival. Results Four patients were implanted with the C-TAH, three as destination therapy (ages 76, 68, 74) and one as bridge to transplant (age 58). They had implant times of 74, 270, 254 and 20 days respectively. All patients were free from hemolysis, clinical neurologic events, clinical evidence of thrombus and device-related infections. Hemodynamic and physical recovery allowed two patients to be discharged home for a cumulative duration of 7 months. The anticoagulation management strategy comprised initial unfractionated heparin, from postoperative day 2, followed by low molecular weight heparin and aspirin. An increased D-dimer level was observed in all patients during months 1 to 4. Temporary suspension of heparin anticoagulation resulted in thrombocytopenia and increased fibrin monomer, reversed by resuming anticoagulation with heparin. Causes of death were device-related (2 cases), respiratory failure and multi-organ failure. Conclusions Preliminary clinical results with the C-TAH demonstrated good safety and performance profiles in patients suffering from biventricular failure, which need to be confirmed in a pivotal study. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
27. Heart transplantation in selected patients aged 60 years and older: a two-decade retrospective and multicentre analysis.
- Author
-
Bosseau, Christian, Lelong, Bernard, Pattier, Sabine, Trochu, Jean-Noël, Roussel, Jean-Christian, Sirinelli, Agnès, Aupart, Michel, Chabanne, Céline, Dorent, Richard, Cantrelle, Christelle, Mabo, Philippe, Leclercq, Christophe, Verhoye, Jean-Philippe, and Flécher, Erwan
- Subjects
- *
HEART failure treatment , *HEART transplantation , *COMPLICATIONS of cardiac surgery , *HEALTH of older people , *SURVIVAL analysis (Biometry) - Abstract
OBJECTIVES: This study analysed survival and long-term outcomes of heart transplantation in patients aged 60 years and older. We also analysed the impact of a national graft allocation priority [Super Emergency (SE)] and compared survival with younger patients in our centres and in France. METHODS: We performed a multicentre (University Hospitals in Nantes, Rennes and Tours), 2-decade retrospective study between 1 January 1994 and 31 December 2013. Elderly recipients were placed on the same list as younger patients; the use of marginal donors remained occasional. RESULTS: A total of 212 patients aged between 60 and 68 years were included. The 1-, 5-, and 10-year survival rates were 83.2%, 77.4% and 63.8%, respectively, which were significantly worse than those of recipients aged <60 years (1-, 5-, and 10-year survival rates of 87.3%, 80.4% and 68.0%, respectively). The postoperative course was acceptable. The main cause of death was malignancy (29.8% in our cohort). Survival was similar between the first and second decades and among the SE group. Our population exhibited better survival than patients <60 years transplanted in France during the same period with 1-, 5-, and 10-year survival rates of 76.8%, 68.0% and 56.3%, respectively. Predictors of survival in the multivariate analysis included ischaemic cardiomyopathy [hazard ratio (HR) 4.1] and postoperative complications, such as dialysis (HR 9.5) and mechanical circulatory support (HR 4.2). CONCLUSIONS: We report positive postoperative course and long-term outcomes after heart transplantation in older recipients using conventional donors. Our satisfactory outcomes may be explained by the stringent selection of recipients combined with regular follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. Characterization of immunogenic Neu5Gc in bioprosthetic heart valves.
- Author
-
Reuven, Eliran Moshe, Leviatan Ben‐Arye, Shani, Marshanski, Tal, Breimer, Michael E., Yu, Hai, Fellah‐Hebia, Imen, Roussel, Jean‐Christian, Costa, Cristina, Galiñanes, Manuel, Mañez, Rafael, Le Tourneau, Thierry, Soulillou, Jean‐Paul, Cozzi, Emanuele, Chen, Xi, and Padler‐Karavani, Vered
- Subjects
- *
IMMUNOGENETICS , *PROSTHETIC heart valves , *HEART valve diseases , *XENOTRANSPLANTATION , *SIALIC acids , *IMMUNOGLOBULINS , *IMMUNOHISTOCHEMISTRY , *THERAPEUTICS - Abstract
Background The two common sialic acids (Sias) in mammals are N-acetylneuraminic acid (Neu5Ac) and its hydroxylated form N-glycolylneuraminic acid (Neu5Gc). Unlike most mammals, humans cannot synthesize Neu5Gc that is considered foreign and recognized by circulating antibodies. Thus, Neu5Gc is a potential xenogenic carbohydrate antigen in bioprosthetic heart valves ( BHV) that tend to deteriorate in time within human patients. Methods We investigated Neu5Gc expression in non-engineered animal-derived cardiac tissues and in clinically used commercial BHV, and evaluated Neu5Gc immunogenicity on BHV through recognition by human anti-Neu5Gc IgG. Results Neu5Gc was detected by immunohistochemistry in porcine aortic valves and in porcine and bovine pericardium. Qualitative analysis of Sia linkages revealed Siaα2-3>Siaα2-6 on porcine/bovine pericardium while the opposite in porcine aortic/pulmonary valve cusps. Similarly, six commercial BHV containing either porcine aortic valve or porcine/bovine/equine pericardium revealed Siaα2-3>Siaα2-6 expression. Quantitative analysis of Sia by HPLC showed porcine/bovine pericardium express 4-fold higher Neu5Gc levels compared to the porcine aortic/pulmonary valves, with Neu5Ac at 6-fold over Neu5Gc. Likewise, Neu5Gc was expressed on commercial BHV (186.3±16.9 pmol Sia/μg protein), with Neu5Ac at 8-fold over Neu5Gc. Affinity-purified human anti-Neu5Gc IgG showing high specificity toward Neu5Gc-glycans (with no binding to Neu5Ac-glycans) on a glycan microarray, strongly bound to all tested commercial BHV, demonstrating Neu5Gc immune recognition in cardiac xenografts. Conclusions We conclusively demonstrated Neu5Gc expression in native cardiac tissues, as well as in six commercial BHV. These Neu5Gc xeno-antigens were recognized by human anti-Neu5Gc IgG, supporting their immunogenicity. Altogether, these findings suggest BHV-Neu5Gc/anti-Neu5Gc may play a role in valve deterioration warranting further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. First clinical use of a bioprosthetic total artificial heart: report of two cases.
- Author
-
Carpentier, Alain, Latrémouille, Christian, Cholley, Bernard, Smadja, David M., Roussel, Jean-Christian, Boissier, Elodie, Trochu, Jean-Noël, Gueffet, Jean-Pierre, Treillot, Michèle, Bizouarn, Philippe, Méléard, Denis, Boughenou, Marie-Fazia, Ponzio, Olivier, Grimmé, Marc, Capel, Antoine, Jansen, Piet, Hagège, Albert, Desnos, Michel, Fabiani, Jean-Noël, and Duveau, Daniel
- Subjects
- *
BIOPROSTHESIS , *HEART transplantation , *PILOT projects , *TREATMENT effectiveness , *DILATED cardiomyopathy , *DISEASE complications , *ARTIFICIAL hearts - Abstract
Background: The development of artificial hearts in patients with end-stage heart disease have been confronted with the major issues of thromboembolism or haemorrhage. Since valvular bioprostheses are associated with a low incidence of these complications, we decided to use bioprosthetic materials in the construction of a novel artificial heart (C-TAH). We report here the device characteristics and its first clinical applications in two patients with end-stage dilated cardiomyopathy. The aim of the study was to evaluate safety and feasibility of the CARMAT TAH for patients at imminent risk of death from biventricular heart failure and not eligible for transplant.Methods: The C-TAH is an implantable electro-hydraulically actuated pulsatile biventricular pump. All components, batteries excepted, are embodied in a single device positioned in the pericardial sac after excision of the native ventricles. We selected patients admitted to hospital who were at imminent risk of death, having irreversible biventricular failure, and not eligible for heart transplantation, from three cardiac surgery centres in France.Findings: The C-TAH was implanted in two male patients. Patient 1, aged 76 years, had the C-TAH implantation on Dec 18, 2013; patient 2, aged 68 years, had the implantation on Aug 5, 2014. The cardiopulmonary bypass times for C-TAH implantation were 170 min for patient 1 and 157 min for patient 2. Both patients were extubated within the first 12 postoperative hours and had a rapid recovery of their respiratory and circulatory functions as well as a normal mental status. Patient 1 presented with a tamponade on day 23 requiring re-intervention. Postoperative bleeding disorders prompted anticoagulant discontinuation. The C-TAH functioned well with a cardiac output of 4·8-5·8 L/min. On day 74, the patient died due to a device failure. Autopsy did not detect any relevant thrombus formation within the bioprosthesis nor the different organs, despite a 50-day anticoagulant-free period. Patient 2 experienced a transient period of renal failure and a pericardial effusion requiring drainage, but otherwise uneventful postoperative course. He was discharged from the hospital on day 150 after surgery with a wearable system without technical assistance. After 4 months at home, the patient suffered low cardiac output. A change of C-TAH was attempted but the patient died of multiorgan failure.Interpretation: This preliminary experience could represent an important contribution to the development of total artificial hearts using bioprosthetic materials.Funding: CARMAT SA. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
30. Early structural valve deterioration of mitroflow aortic bioprosthesis: mode, incidence, and impact on outcome in a large cohort of patients.
- Author
-
Sénage, Thomas, Le Tourneau, Thierry, Foucher, Yohann, Pattier, Sabine, Cueff, Caroline, Michel, Magali, Serfaty, Jean-Michel, Mugniot, Antoine, Périgaud, Christian, Carton, Hubert François, Al Habash, Ousama, Baron, Olivier, and Roussel, Jean Christian
- Abstract
BACKGROUND: Structural valve deterioration (SVD) is a major flaw of bioprostheses. Early SVD has been suspected in the last models of Mitroflow bioprosthesis. We sought to assess the incidence, mode, and impact of SVD on outcome in a large series of Mitroflow aortic valve replacement. METHODS AND RESULTS: Six hundred seventeen consecutive patients (aged 76.1±6.3 years) underwent aortic valve replacement with a Mitroflow prosthesis (models 12A/LX) between 2002 and 2007. By echocardiography, 39 patients developed early SVD (1.66% per patient-year), with stenosis as the main mode (n=36). Mean delay to SVD was only 3.8±1.4 years, and 5-year SVD-free survival was 91.6% (95% confidence interval [CI], 88.7-94.7) for the whole cohort and 79.8% (95% CI, 71.2-89.4) and 94.0% (95% CI, 90.3-97.8) for 19- and 21-mm sizes, respectively. Among the 39 patients with SVD, 13 patients (33%) had an accelerated SVD once the mean gradient exceeded 30 mm Hg. Valve-related death was 46.2% in this SVD subgroup. Five-year overall survival was 69.6% (95% CI, 65.7-73.9). In multivariable analysis, SVD was the strongest correlate of overall mortality (hazard ratio=7.7; 95% CI, 4.4-13.6). CONCLUSIONS: Early SVD is frequent in Mitroflow bioprosthesis (models 12A/LX), especially for small sizes (19 and 21 mm), and reduces overall survival. An unpredictable accelerated pattern of SVD constitutes a life-threatening condition. In view of the large number of Mitroflow valves implanted worldwide, one can expect an epidemic of SVD and valve-related deaths, which represents a major public health issue, especially in the elderly. Hence, a close follow-up with yearly echocardiography after Mitroflow implantation is advisable. An urgent reoperation should be discussed in patients with severe SVD even though they are still asymptomatic. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
31. Early Structural Valve Deterioration of Mitroflow Aortic Bioprosthesis.
- Author
-
Sénage, Thomas, Le Tourneau, Thierry, Foucher, Yohann, Pattier, Sabine, Cueff, Caroline, Michel, Magali, Serfaty, Jean-Michel, Mugniot, Antoine, Périgaud, Christian, Carton, Hubert François, Al Habash, Ousama, Baron, Olivier, and Roussel, Jean Christian
- Subjects
- *
PROSTHETIC heart valves , *HEART valve surgery , *STENOSIS , *BLOOD flow measurement ,AORTIC valve surgery - Abstract
Background--Structural valve deterioration (SVD) is a major flaw of bioprostheses. Early SVD has been suspected in the last models of Mitroflow bioprosthesis. We sought to assess the incidence, mode, and impact of SVD on outcome in a large series of Mitroflow aortic valve replacement. Methods and Results--Six hundred seventeenconsecutive patients (aged 76.1±6.3 years) underwent aortic valve replacement with a Mitroflow prosthesis (models 12A/LX) between 2002 and 2007. By echocardiography, 39 patients developed early SVD (1.66% per patient-year), with stenosis as the main mode (n=36). Mean delay to SVD was only 3.8±1.4 years, and 5-year SVD-free survival was 91.6% (95% confidence interval [Cl], 88.7-94.7) for the whole cohort and 79.8% (95% Cl, 71.2-89.4) and 94.0% (95% Cl, 90.3-97.8) for 19- and 21-mm sizes, respectively. Among the 39 patients with SVD, 13 patients (33%) had an accelerated SVD once the mean gradient exceeded 30 mmHg. Valve-related death was 46.2% in this SVD subgroup. Five-year overall survival was 69.6% (95% Cl, 65.7-73.9). In multivariable analysis, SVD was the strongest correlate of overall mortality (hazard ratio=7.7; 95% Cl, 4.4-13.6). Conclusions--Early SVD is frequent in Mitroflow bioprosthesis (models 12A/LX), especially for small sizes (19 and 21 mm), and reduces overall survival. An unpredictable accelerated pattern of SVD constitutes a life-threatening condition. In view of the large number of Mitroflow valves implanted worldwide, one can expect an epidemic of SVD and valve- related deaths, which represents a major public health issue, especially in the elderly. Hence, a close follow-up with yearly echocardiography after Mitroflow implantation is advisable. An urgent reoperation should be discussed in patients with severe SVD even though they are still asymptomatic. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
32. Bioprosthetic Total Artificial Heart Induces a Profile of Acquired Hemocompatibility With Membranes Recellularization.
- Author
-
Smadja, David M., Saubaméa, Bruno, Susen, Sophie, Kindo, Michel, Bruneval, Patrick, Van Belle, Eric, Jansen, Piet, Roussel, Jean-Christian, Latrémouille, Christian, and Carpentier, Alain
- Subjects
- *
BIOPROSTHESIS , *ARTIFICIAL hearts , *MEDICAL registries , *MEDICAL databases , *BIOLOGICAL membranes , *CARDIAC surgery , *MEDICAL equipment reliability , *RESEARCH , *HEMOLYSIS & hemolysins , *AUTOPSY , *RESEARCH methodology , *SURGICAL complications , *EVALUATION research , *TREATMENT effectiveness , *COMPARATIVE studies , *MATERIALS testing , *BIOPHYSICS , *DISEASE complications - Published
- 2017
- Full Text
- View/download PDF
33. Human comparative experimental study of surgical treatment of atrial fibrillation by epicardial techniques.
- Author
-
El Arid, Jean-Marc, Sénage, Thomas, Toquet, Claire, Al Habash, Ousama, Mugniot, Antoine, Baron, Olivier, and Roussel, Jean-Christian
- Subjects
- *
ATRIAL fibrillation , *MEDICAL imaging systems , *CARDIOPULMONARY bypass , *ISCHEMIA , *CARDIAC surgery - Abstract
Background: To set up an experimental model of cadaveric heart in order to evaluate and compare histologic transmurality of lesions immediately caused by different energy sources of anti-arrhythmic epicardial devices. Methods: Procedures were performed on a cadaveric human heart in orthotopic position with an ischemic time of 48 h at 37° and supported through the use of cardiopulmonary bypass. Three anti-arrhythmic epicardial devices were studied: the bipolar forceps Cardioblate BP (Medtronic) for the radiofrequency, the Epicor Ultracinch LP Ablation device (St. Jude) for ultrasound and the Cardioblate CryoFlex (Medtronic) device for cryoablation. Histological features of lesions made at the pulmonary venous confluence assessed the effectiveness of different energy sources. Results: Over 45 experimentations performed, only 28 were considered correct and retained for histological analysis. Three distinct groups were studied according to the type of procedure performed: group 1 (Radiofrequency, n = 12), group 2 (ultrasound, n = 4), group 3 (cryoablation, n = 10) and controls (n = 2). All analysed samples showed histological changes with a success rates of transmurality of 33% for radiofrequency, 25% for ultrasound and 90% for cryotherapy (p <0.001). The average length of transmurality, when it was reached and the proportion of transmurality over the total length of the lesion were respectively 12 ± 6 mm and 37 ± 18% for group 1, 10 mm and 33% for group 2 and 11.1 ± 1.1 mm and 35 ± 5% for group 3. Conclusion: Immediate detectable histological transmural lesions after epicardial procedure are discontinuous whatever the kind of energy source tested in this work and it strongly encourages the repetition of radiofrequency procedures. Nevertheless, our experimental model seems inadequate to assess ultrasound energy efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
34. The effect of mitoxantrone on anti-pig immunization in baboons.
- Author
-
Petzold, Thomas, Barreau, Nathalie, Ashton-Chess, Joanna, Edan, Gilles, Boulday, Gwénola, Roussel, Jean-christian, Berre, Ludmilla Le, Minault, David, Soulillou, Jean-paul, and Blancho, Gilles
- Subjects
- *
XENOGRAFTS , *MITOXANTRONE hydrochloride , *ONCOLOGY , *MULTIPLE sclerosis , *BABOONS - Abstract
Abstract: Besides virological and physiological concerns, the success of xenotransplantation (Xt) is still dependent on the prevention of delayed xenograft rejection (DXR). Although multifactorial, DXR is mainly due to xenonatural antibody (Ab) recognizing their xenogenic antigen (Ag) followed by complement activation. Despite the use of intensive treatments capable of inhibiting the humoral response, DXR can still not be avoided and always occurs within weeks following transplantation. Moreover, these latter treatments currently used in Xt could not be used clinically in humans because of their high risk of over-immunosuppressing the patients. Mitoxantrone (Mx) is a drug well known for its antiproliferative properties and is used clinically in oncology and in the treatment of relapsing multiple sclerosis. In models of arthritis in rats, it has been shown to be 10 to 20 times more powerful than cyclophosphamide (CyP) at blocking both inflammatory and B-cell responses. Because of its B-cell inhibitory capacity and considering the implication of the humoral response in xenograft rejection, we have compared Mx with CyP for its ability to block in vivo anti-pig immunization induced via subcutaneous injections of pig red blood cells into baboons. Neither drug was able to inhibit the anti-pig responses following the first and second immunizations, emphasizing the particularity of preformed Ab responses. However, the rise in Ab in the Mx treated animals was significantly delayed as compared with the non-treated as well as the CyP treated animals and was mainly because of a profound depletion of circulating B-cells. Mx displays an interesting antihumoral effect that we now intend to test in a pig kidney to baboon Xt model, with anticipated administration of the drug allowing an early B-cell depletion. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
35. Association between Neu5Gc carbohydrate and serum antibodies against it provides the molecular link to cancer: French NutriNet-Santé study.
- Author
-
Bashir, Salam, Fezeu, Leopold K., Leviatan Ben-Arye, Shani, Yehuda, Sharon, Reuven, Eliran Moshe, Szabo de Edelenyi, Fabien, Fellah-Hebia, Imen, Le Tourneau, Thierry, Imbert-Marcille, Berthe Marie, Drouet, Emmanuel B., Touvier, Mathilde, Roussel, Jean-Christian, Yu, Hai, Chen, Xi, Hercberg, Serge, Cozzi, Emanuele, Soulillou, Jean-Paul, Galan, Pilar, and Padler-Karavani, Vered
- Subjects
- *
ANTIBODY diversity , *CARBOHYDRATES , *IMMUNOGLOBULINS , *FOOD diaries , *SERUM - Abstract
Background: High consumption of red and processed meat is commonly associated with increased cancer risk, particularly colorectal cancer. Antibodies against the red meat-derived carbohydrate N-glycolylneuraminic acid (Neu5Gc) exacerbate cancer in "human-like" mice. Human anti-Neu5Gc IgG and red meat are both independently proposed to increase cancer risk, yet how diet affects these antibodies is largely unknown.Methods: We used world global data to demonstrate that colorectal cancer incidence and mortality are associated with increased national meat consumption. In a well-defined large cohort, we used glycomics to measure daily Neu5Gc intake from red meat and dairy, and investigated serum as well as affinity-purified anti-Neu5Gc antibodies. Based on 24-h dietary records, daily Neu5Gc intake was calculated for 19,621 subjects aged ≥ 18 years of the NutriNet-Santé study. Serum and affinity-purified anti-Neu5Gc antibodies were evaluated by ELISA and glycan microarrays in representative 120 individuals, each with at least eighteen 24-h dietary records (aged 45-60, Q1-Q4; aged > 60, Q1 and Q4; 10 men/women per quartile).Results: We found that high-Neu5Gc diet, gender, and age affect the specificity, levels, and repertoires of anti-Neu5Gc IgG immune responses, but not their affinity. Men consumed more Neu5Gc than women, mostly from red meat (p = 0.0015), and exhibited higher overall serum anti-Neu5Gc IgG levels by ELISA (3.94 ng/μl versus 2.22 ng/μl, respectively; p = 0.039). Detailed glycan microarray analysis against 56 different glycans revealed high Neu5Gc-specificity with increased anti-Neu5Gc IgG and altered repertoires, associated with higher consumption of Neu5Gc from red meat and cow dairy. Affinity purification of serum anti-Neu5Gc antibodies revealed increased levels and biased array repertoire patterns, without an increase in antibody affinity, in individuals consuming higher Neu5Gc levels. Furthermore, in a high-meat diet, antibody diversity patterns on glycan microarrays shifted towards Neu5Gcα3-linked glycans, increasing the α3/α6-glycans ratio score.Conclusions: We found a clear link between the levels and repertoire of serum anti-Neu5Gc IgG and Neu5Gc intake from red meat and dairy. These precise rational methodologies allowed to develop a Gcemic index to simplify the assessment of Neu5Gc in foods that could potentially be adapted for dietary recommendations to reduce cancer risk. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
36. Elicited and pre‐existing anti‐Neu5Gc antibodies differentially affect human endothelial cells transcriptome.
- Author
-
Le Berre, Ludmilla, Danger, Richard, Mai, Hoa L., Amon, Ron, Leviatan Ben‐Arye, Shani, Bruneau, Sarah, Senage, Thomas, Perreault, Helene, Teraiya, Milan, Nguyen, Thi Van Ha, Le Tourneau, Thierry, Yu, Hai, Chen, Xi, Galli, Cesare, Roussel, Jean‐Christian, Manez, Rafael, Costa, Cristina, Brouard, Sophie, Galinanes, Manuel, and Harris, Kristina M.
- Subjects
- *
ENDOTHELIAL cells , *IMMUNOGLOBULINS , *GLOBULINS , *XENOTRANSPLANTATION , *CHEMOTAXIS - Abstract
Humans cannot synthesize N‐glycolylneuraminic acid (Neu5Gc) but dietary Neu5Gc can be absorbed and deposited on endothelial cells (ECs) and diet‐induced anti‐Neu5Gc antibodies (Abs) develop early in human life. While the interaction of Neu5Gc and diet‐induced anti‐Neu5Gc Abs occurs in all normal individuals, endothelium activation by elicited anti‐Neu5Gc Abs following a challenge with animal‐derived materials, such as following xenotransplantation, had been postulated. Ten primary human EC preparations were cultured with affinity‐purified anti‐Neu5Gc Abs from human sera obtained before or after exposure to Neu5Gc‐glycosylated rabbit IgGs (elicited Abs). RNAs of each EC preparation stimulated in various conditions by purified Abs were exhaustively sequenced. EC transcriptomic patterns induced by elicited anti‐Neu5Gc Abs, compared with pre‐existing ones, were analyzed. qPCR, cytokines/chemokines release, and apoptosis were tested on some EC preparations. The data showed that anti‐Neu5Gc Abs induced 967 differentially expressed (DE) genes. Most DE genes are shared following EC activation by pre‐existing or anti‐human T‐cell globulin (ATG)‐elicited anti‐Neu5Gc Abs. Compared with pre‐existing anti‐Neu5Gc Abs, which are normal component of ECs environment, elicited anti‐Neu5Gc Abs down‐regulated 66 genes, including master genes of EC function. Furthermore, elicited anti‐Neu5Gc Abs combined with complement‐containing serum down‐regulated most transcripts mobilized by serum alone. Both types of anti‐Neu5Gc Abs‐induced a dose‐ and complement‐dependent release of selected cytokines and chemokines. Altogether, these data show that, compared with pre‐existing anti‐Neu5Gc Abs, ATG‐elicited anti‐Neu5Gc Abs specifically modulate genes related to cytokine responses, MAPkinase cascades, chemotaxis, and integrins and do not skew the EC transcriptome toward a pro‐inflammatory profile in vitro. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Generation of cattle knockout for galactose‐α1,3‐galactose and N‐glycolylneuraminic acid antigens.
- Author
-
Perota, Andrea, Lagutina, Irina, Duchi, Roberto, Zanfrini, Elisa, Lazzari, Giovanna, Judor, Jean Paul, Conchon, Sophie, Bach, Jean Marie, Bottio, Tomaso, Gerosa, Gino, Costa, Cristina, Galiñanes, Manuel, Roussel, Jean Christian, Padler‐Karavani, Vered, Cozzi, Emanuele, Soulillou, Jean Paul, and Galli, Cesare
- Subjects
- *
GALACTOSE , *SOMATIC cell nuclear transfer , *CATTLE , *HEART valves , *ANTIGENS , *REPRODUCTION - Abstract
Two well‐characterized carbohydrate epitopes are absent in humans but present in other mammals. These are galactose‐α1,3‐galactose (αGal) and N‐glycolylneuraminic acid (Neu5Gc) which are introduced by the activities of two enzymes including α(1,3) galactosyltransferase (encoded by the GGTA1 gene) and CMP‐Neu5Gc hydroxylase (encoded by the CMAH gene) that are inactive in humans but present in cattle. Hence, bovine‐derived products are antigenic in humans who receive bioprosthetic heart valves (BHVs) or those that suffer from red meat syndrome. Using programmable nucleases, we disrupted (knockout, KO) GGTA1 and CMAH genes encoding for the enzymes that catalyse the synthesis of αGal and Neu5Gc, respectively, in both male and female bovine fibroblasts. The KO in clonally selected fibroblasts was detected by polymerase chain reaction (PCR) and confirmed by Sanger sequencing. Selected fibroblasts colonies were used for somatic cell nuclear transfer (SCNT) to produce cloned embryos that were implanted in surrogate recipient heifers. Fifty‐three embryos were implanted in 33 recipients heifers; 3 pregnancies were carried to term and delivered 3 live calves. Primary cell cultures were established from the 3 calves and following molecular analyses confirmed the genetic deletions. FACS analysis showed the double‐KO phenotype for both antigens confirming the mutated genotypes. Availability of such cattle double‐KO model lacking both αGal and Neu5Gc offers a unique opportunity to study the functionality of BHV manufactured with tissues of potentially lower immunogenicity, as well as a possible new clinical approaches to help patients with red meat allergy syndrome due to the presence of these xenoantigens in the diet. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
38. Human comparative experimental study of surgical treatment of atrial fibrillation by epicardial techniques.
- Author
-
El Arid, Jean-Marc, Sénage, Thomas, Toquet, Claire, Al Habash, Ousama, Mugniot, Antoine, Baron, Olivier, and Roussel, Jean-Christian
- Abstract
Background: To set up an experimental model of cadaveric heart in order to evaluate and compare histologic transmurality of lesions immediately caused by different energy sources of anti-arrhythmic epicardial devices.Methods: Procedures were performed on a cadaveric human heart in orthotopic position with an ischemic time of 48 h at 37° and supported through the use of cardiopulmonary bypass. Three anti-arrhythmic epicardial devices were studied: the bipolar forceps Cardioblate BP (Medtronic) for the radiofrequency, the Epicor Ultracinch LP Ablation device (St. Jude) for ultrasound and the Cardioblate CryoFlex (Medtronic) device for cryoablation. Histological features of lesions made at the pulmonary venous confluence assessed the effectiveness of different energy sources.Results: Over 45 experimentations performed, only 28 were considered correct and retained for histological analysis. Three distinct groups were studied according to the type of procedure performed: group 1 (Radiofrequency, n = 12), group 2 (ultrasound, n = 4), group 3 (cryoablation, n = 10) and controls (n = 2). All analysed samples showed histological changes with a success rates of transmurality of 33% for radiofrequency, 25% for ultrasound and 90% for cryotherapy (p <0.001). The average length of transmurality, when it was reached and the proportion of transmurality over the total length of the lesion were respectively 12 ± 6 mm and 37 ± 18% for group 1, 10 mm and 33% for group 2 and 11.1 ± 1.1 mm and 35 ± 5% for group 3.Conclusion: Immediate detectable histological transmural lesions after epicardial procedure are discontinuous whatever the kind of energy source tested in this work and it strongly encourages the repetition of radiofrequency procedures. Nevertheless, our experimental model seems inadequate to assess ultrasound energy efficacy. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.